Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1980 Nov;42(5):668–676. doi: 10.1038/bjc.1980.300

Criteria for the selection of second-generation platinum compounds.

R Shepherd, H Kusnierczyk, M Jones, K R Harrap
PMCID: PMC2010534  PMID: 7193043

Abstract

Our selection of a potential second-generation platinum compound began with an initial short list of 8 compounds selected on the basis of antitumour and toxicity studies in mice. We now report further, more detailed investigations of the renal toxicity and antitumour activity of one of these compounds, cis-dichloro trans-dihydroxy bis isopropylamine platinum (IV) (CHIP), in comparison with cis-dichloro diammine platinum (II) (Neoplatin). CHIP was a more effective anti-tumour agent against both alkylating-agent sensitive and resistant strains of the Yoshida sarcoma (YSS and YSR respectively) than was Neoplatin. In addition CHIP produced negligible kidney toxicity as measured by blood urea levels. We have also compared the effects of these two drugs on nuclear-protein phosphorylation, in an attempt to gain insight into their molecular mode of action. Both Neoplatin and CHIP induced increased nuclear-protein phosphorylation in the YSS tumour cells, and loss of condensed chromatin. However, CHIP also induced increased nuclear-protein phosphorylation and loss of condensed chromatin in the YSR tumour cells. These changes correlated well with cell death. In addition Neoplatin, but not CHIP, treatment caused increased nuclear-protein phosphorylation in kidney tissues. This correlated with kidney damage as measured by blood urea levels. These selection criteria suggested that CHIP would be a more selective antitumour agent than Neoplatin, and will provide a basis for its comparison with the other 7 compounds.

Full text

PDF
668

Images in this article

673Fig. 8
on p.673
673Fig. 9
on p.673
674Fig. 10
on p.674

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Braddock P. D., Connors T. A., Jones M., Khokhar A. R., Melzack D. H., Tobe M. L. Structure and activity relationships of platinum complexes with anti-tumour activity. Chem Biol Interact. 1975 Sep;11(3):145–161. doi: 10.1016/0009-2797(75)90095-2. [DOI] [PubMed] [Google Scholar]
  2. Connors T. A., Jones M., Ross W. C., Braddock P. D., Khokhar A. R., Tobe M. L. New platinum complexes with anti-tumour activity. Chem Biol Interact. 1972 Nov;5(6):415–424. doi: 10.1016/0009-2797(72)90078-6. [DOI] [PubMed] [Google Scholar]
  3. Dentino M., Luft F. C., Yum M. N., Williams S. D., Einhorn L. H. Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer. 1978 Apr;41(4):1274–1281. doi: 10.1002/1097-0142(197804)41:4<1274::aid-cncr2820410410>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  4. Gonzales-Vitale J. C., Hayes D. M., Cvitkovic E., Sternberg S. S. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer. 1977 Apr;39(4):1362–1371. doi: 10.1002/1097-0142(197704)39:4<1362::aid-cncr2820390403>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  5. Harrap K. R., Furness M. E. The cytotoxicity of chlorambucil and its associated effects on NAD metabolism. Eur J Cancer. 1973 May;9(5):343–351. doi: 10.1016/0014-2964(73)90049-2. [DOI] [PubMed] [Google Scholar]
  6. Harrap K. R., Hill B. T. The selectivity of action of alkylating agents and drug resistance. II. A comparison of the effects of alkylating drugs on growth inhibition and cell size in sensitive and resistant strains of the Yoshida ascites sarcoma. Br J Cancer. 1969 Mar;23(1):227–234. doi: 10.1038/bjc.1969.31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hayes D. M., Cvitkovic E., Golbey R. B., Scheiner E., Helson L., Krakoff I. H. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer. 1977 Apr;39(4):1372–1381. doi: 10.1002/1097-0142(197704)39:4<1372::aid-cncr2820390404>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  8. Higby D. J., Wallace H. J., Jr, Albert D. J., Holland J. F. Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors. Cancer. 1974 May;33(5):1219–1215. doi: 10.1002/1097-0142(197405)33:5<1219::aid-cncr2820330505>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  9. KARNOVSKY M. J. Simple methods for "staining with lead" at high pH in electron microscopy. J Biophys Biochem Cytol. 1961 Dec;11:729–732. doi: 10.1083/jcb.11.3.729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Krauss S., Tornyos K., DeSimone P., Lowenbraun S., McKeown J., Solomon A., Sonoda T. cis-Dichlorodiammineplatinum(II) and hexamethylmelamine in the treatment of non-oat cell lung cancer: a pilot study of the Southeastern Cancer Study Group. Cancer Treat Rep. 1979 Mar;63(3):391–393. [PubMed] [Google Scholar]
  11. LAMERTON L. F., ELSON L. A., CHRISTENSEN W. R. A study of the phases of radiation response in the rat. I. The effects of uniform whole body irradiation. Br J Radiol. 1953 Oct;26(310):510–518. doi: 10.1259/0007-1285-26-310-510. [DOI] [PubMed] [Google Scholar]
  12. Prestayko A. W., D'Aoust J. C., Issell B. F., Crooke S. T. Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat Rev. 1979 Mar;6(1):17–39. doi: 10.1016/s0305-7372(79)80057-2. [DOI] [PubMed] [Google Scholar]
  13. ROSENBERG B., VANCAMP L., KRIGAS T. INHIBITION OF CELL DIVISION IN ESCHERICHIA COLI BY ELECTROLYSIS PRODUCTS FROM A PLATINUM ELECTRODE. Nature. 1965 Feb 13;205:698–699. doi: 10.1038/205698a0. [DOI] [PubMed] [Google Scholar]
  14. Randolph V. L., Wittes R. E. Weekly administration of cis-diamminedichloroplatinum (II) without hydration or osmotic diuresis. Eur J Cancer. 1978 Jul;14(7):753–756. doi: 10.1016/0014-2964(78)90004-x. [DOI] [PubMed] [Google Scholar]
  15. Rickwood D., Riches P. G., Maggillivray A. J. Studies of the in vitro phosphorylation of chromatin non-histone proteins in isolated nuclei. Biochim Biophys Acta. 1973 Feb 23;299(1):162–171. doi: 10.1016/0005-2787(73)90408-5. [DOI] [PubMed] [Google Scholar]
  16. Roberts J. J., Pascoe J. M. Cross-linking of complementary strands of DNA in mammalian cells by antitumour platinum compounds. Nature. 1972 Feb 4;235(5336):282–284. doi: 10.1038/235282a0. [DOI] [PubMed] [Google Scholar]
  17. Roberts J. J., Thomson A. J. The mechanism of action of antitumor platinum compounds. Prog Nucleic Acid Res Mol Biol. 1979;22:71–133. doi: 10.1016/s0079-6603(08)60799-0. [DOI] [PubMed] [Google Scholar]
  18. Rosenberg B., Renshaw E., Vancamp L., Hartwick J., Drobnik J. Platinum-induced filamentous growth in Escherichia coli. J Bacteriol. 1967 Feb;93(2):716–721. doi: 10.1128/jb.93.2.716-721.1967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Rosenberg B., VanCamp L., Trosko J. E., Mansour V. H. Platinum compounds: a new class of potent antitumour agents. Nature. 1969 Apr 26;222(5191):385–386. doi: 10.1038/222385a0. [DOI] [PubMed] [Google Scholar]
  20. Rosenoer V. M., Mitchley B. C., Roe F. J., Connors T. A. Walker carcinosarcoma 256 in study of anticancer agents. I. Method for simultaneous assessment of therapeutic value and toxicity. Cancer Res. 1966 Aug;26(8 Pt 2):937–941. [PubMed] [Google Scholar]
  21. Rozencweig M., von Hoff D. D., Slavik M., Muggia F. M. Cis-diamminedichloroplatinum (II). A new anticancer drug. Ann Intern Med. 1977 Jun;86(6):803–812. doi: 10.7326/0003-4819-86-6-803. [DOI] [PubMed] [Google Scholar]
  22. Wilkinson R., Birbeck M. S., Harrap K. R. Enhancement of the nuclear reactivity of alkylating agents by prednisolone. Cancer Res. 1979 Oct;39(10):4256–4262. [PubMed] [Google Scholar]
  23. Wiltshaw E., Kroner T. Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep. 1976 Jan;60(1):55–60. [PubMed] [Google Scholar]
  24. Zwelling L. A., Kohn K. W., Ross W. E., Ewig R. A., Anderson T. Kinetics of formation and disappearance of a DNA cross-linking effect in mouse leukemia L1210 cells treated with cis- and trans-diamminedichloroplatinum(II). Cancer Res. 1978 Jun;38(6):1762–1768. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES